• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

    9/14/23 12:58:49 PM ET
    $AMBI
    $AVTX
    $AXLA
    $BIMI
    Environmental Services
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMBI alert in real time by email

    First Wave BioPharma, Inc. (NASDAQ:FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi.

    PFSweb, Inc. (NASDAQ:PFSW) gained 48.3% to $7.43 after GXO Logistics announced it will acquire the company.

    TradeUP Acquisition Corp. (NASDAQ:UPTD) shares climbed 45.8% to $11.08.

    Taseko Mines Limited (NYSE:TGB) gained 22.3% to $1.59.

    Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares gained 22% to $0.2730 after jumping 81% on Wednesday. Avalo Therapeutics recently agreed to divest AVTX-800 series.

    NeuBase Therapeutics, Inc. (NASDAQ:NBSE) gained 20.3% to $1.48. Symetryx said on Sept. 13, 2023, sent an email to Neubase proposing a specific company as a potential merger candidate and will facilitate an introduction to this potential merger candidate if there is interest.

    MYT Netherlands Parent B.V. (NASDAQ:MYTE) jumped 15.4% to $4.3300 after the company reported fourth-quarter financial results.

    Soluna Holdings, Inc. (NASDAQ:SLNH) gained 13.4% to $0.2064 after reporting a narrower quarterly loss.

    Nikola Corporation (NASDAQ:NKLA) jumped 13.4% to $0.9869. Nikola CEO Steve Girsky on Wednesday termed the several cases of fire reported with its battery electric trucks a ‘setback’ and detailed the measures being undertaken to fix the issue.

    Trinseo PLC (NYSE:TSE) rose 11.9% to $8.84.

    Alaunos Therapeutics, Inc. (NASDAQ:TCRT) surged 11.4% to $0.1360.

    Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) jumped 11.1% to $5.72.

    Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) rose 10.4% to $0.4525. Eiger BioPharmaceuticals shares fell over 40% on Wednesday after the company announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta.

    Uniti Group Inc. (NASDAQ:UNIT) jumped 9.7% to $5.29.

    Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) shares climbed 8.1% to $0.3050.

    TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares rose 6.2% to $0.9555.

    Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 5.7% to $0.4660. Novo Integrated Sciences disclosed that its IoNovo for Kids pure iodine oral spray was granted a registration number and regulatory approval by Turkey's Ministry of Health.

    Losers

    Sezzle Inc. (NASDAQ:SEZL) shares fell 76% to $20.54.

    Clearmind Medicine Inc. (NASDAQ:CMND) fell 53.4% to $0.1870. Clearmind Medicine announced pricing of $2.25 million public offering of 7.5 million shares at $0.30/share.

    BIOLASE, Inc. (NASDAQ:BIOL) fell 37.5% to $2.0360 after the company announced pricing of a $4.5 million underwritten public offering of Series J Convertible Redeemable Preferred Stock and warrants.

    OKYO Pharma Limited (NASDAQ:OKYO) fell 22.7% to $1.53 in pre-market trading after the company announced a $4 million public offering of ordinary shares.

    IBEX Limited (NASDAQ:IBEX) fell 21.4% to $14.26 after the company reported downbeat results for its fourth quarter and issued weak FY24 revenue outlook.

    Bionomics Limited (NASDAQ:BNOX) fell 20.6% to $1.42 after the company announced an update on its α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator collaboration with Merck.

    MicroCloud Hologram Inc. (NASDAQ:HOLO) declined 19.4% to $1.7074.

    Harpoon Therapeutics, Inc. (NASDAQ:HARP) dipped 19% to $5.30 after AbbVie decided not to exercise the exclusive license option for the HPN217 program.

    ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) fell 18.1% to $0.1556.

    Super League Enterprise, Inc. (NASDAQ:SLE) dipped 16.4% to $1.83.

    Axcella Health Inc. (NASDAQ:AXLA) fell 15.1% to $1.0101.

    BIMI International Medical, Inc. (NASDAQ:BIMI) tumbled 14.8% to $1.61.

    Impel Pharmaceuticals Inc. (NASDAQ:IMPL) fell 14.4% to $0.6850 after jumping 45% on Wednesday.

    PureCycle Technologies, Inc. (NASDAQ:PCT) shares fell 13.4% to $6.55.

    Bionomics Limited (NASDAQ:BNOX) shares fell 13.1% to $1.72.

    Ivanhoe Electric Inc. (NYSE:IE) fell 10.8% to $13.72 after the company priced its public offering of 11,851,852 common shares at $13.50 per share.

    SIMPPLE LTD. (NASDAQ:SPPL) fell 10.5% to $4.3789. SIMPPLE priced its initial public offering of 1.6 million ordinary shares at $5.25/share for total of $8.4 million.

    Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) declined 9.8% to $4.9005. The stock is falling on heavy volume Thursday morning with nearly 4 million shares exchanging hands, and fast approaching the trailing 100 day average volume of 4.8 million shares.

    Radiant Logistics, Inc. (NYSE:RLGT) declined 9.4% to $6.04 following weak quarterly sales.

    CS Disco, Inc. (NYSE:LAW) fell 8.8% to $7.06. MoffettNathanson downgraded CS Disco from Outperform to Market Perform.

    Ambipar Emergency Response (NYSE:AMBI) declined 7.4% to $8.66.

    Genius Sports Limited (NYSE:GENI) fell 7.4% to $5.59. Genius Sports announced pricing of secondary offering of 20 million shares at $5.35 per share by selling shareholder.

    Vital Energy, Inc. (NYSE:VTLE) shares fell 5.8% to $55.54 after the company announced public offering of 2.5 million shares of its common stock and also plans offering of senior notes.

    Now Read This: Ethereum Tops This Key Level Following PPI Data; Hedera Emerges As Top Gainer

    Get the next $AMBI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMBI
    $AVTX
    $AXLA
    $BIMI

    CompanyDatePrice TargetRatingAnalyst
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    Sezzle Inc.
    $SEZL
    2/12/2026$85.00Buy
    Needham
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Genius Sports Limited
    $GENI
    1/22/2026$10.00Hold
    Stifel
    Genius Sports Limited
    $GENI
    1/9/2026$16.00Equal Weight → Overweight
    Wells Fargo
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Soluna Holdings Inc.
    $SLNH
    12/11/2025$5.00Neutral → Buy
    H.C. Wainwright
    More analyst ratings

    $AMBI
    $AVTX
    $AXLA
    $BIMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Needham initiated coverage on Sezzle with a new price target

    Needham initiated coverage of Sezzle with a rating of Buy and set a new price target of $85.00

    2/12/26 7:13:35 AM ET
    $SEZL
    Finance: Consumer Services
    Finance

    $AMBI
    $AVTX
    $AXLA
    $BIMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Soluna Closes $53M Briscoe Wind Farm Acquisition; Achieves Vertical Integration

    $6–$11M Year-One Projected EBITDA | 300 MW AI Campus Expansion at Project Dorothy Soluna Holdings, Inc. ("Soluna" or the "Company") (NASDAQ:SLNH), a developer of green data centers that converts renewable energy into computing power, today announced that it has closed the acquisition of the 150 MW Briscoe Wind Farm in West Texas for a total purchase price of $53.0 million. The transaction was financed through cash on the balance sheet and debt. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402681640/en/Soluna's acquisition of the Briscoe Wind Farm marks a structural milestone in Soluna's evolution from co-location to full

    4/2/26 7:30:00 AM ET
    $SLNH
    EDP Services
    Technology

    Lixiang Education Announces Plan to Implement ADS Ratio Change

    LISHUI, China, April 01, 2026 (GLOBE NEWSWIRE) -- Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH), a prestigious private education service provider in China, today announced that it plans to change the ratio of its American depositary shares ("ADSs") to its ordinary shares (the "ADS Ratio"), par value US$0.0001 per share, from the current ADS Ratio of one (1) ADS to one hundred (100) ordinary shares to a new ADS Ratio of one (1) ADS to one thousand (1,000) ordinary shares (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on or about April 20, 2026 (the "Effective Date"). For the Company's ADS holders, the change in the ADS Ratio will have the

    4/1/26 5:00:00 PM ET
    $LXEH
    Other Consumer Services
    Real Estate

    ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

    ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread and perpetuation of inflammation by uniquely inhibiting ASC specks. Lead indication: Cardiometabolic conditions associated with obesityValue driving milestones: File IND Q4-2026; Phase 1 SAD read-out Q1-2027 Cholesterol Efflux Mediator VAR 200 is expected to be a disease-modifying renal drug by targeting unaddress

    3/31/26 5:05:00 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMBI
    $AVTX
    $AXLA
    $BIMI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMBI
    $AVTX
    $AXLA
    $BIMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Brading Lee Dickson

    4 - Sezzle Inc. (0001662991) (Issuer)

    4/3/26 4:12:36 PM ET
    $SEZL
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Youakim Charles

    4 - Sezzle Inc. (0001662991) (Issuer)

    4/3/26 4:12:45 PM ET
    $SEZL
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Hollis Kerissa

    4 - Sezzle Inc. (0001662991) (Issuer)

    4/3/26 4:12:30 PM ET
    $SEZL
    Finance: Consumer Services
    Finance

    $AMBI
    $AVTX
    $AXLA
    $BIMI
    SEC Filings

    View All

    Soluna Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Soluna Holdings, Inc (0000064463) (Filer)

    4/3/26 4:19:07 PM ET
    $SLNH
    EDP Services
    Technology

    Soluna Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Soluna Holdings, Inc (0000064463) (Filer)

    4/2/26 7:30:08 AM ET
    $SLNH
    EDP Services
    Technology

    SEC Form 6-K filed by Lixiang Education Holding Co. Ltd.

    6-K - Lixiang Education Holding Co. Ltd. (0001814067) (Filer)

    4/1/26 5:00:02 PM ET
    $LXEH
    Other Consumer Services
    Real Estate

    $AMBI
    $AVTX
    $AXLA
    $BIMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Hochman David P bought $42,900 worth of shares (10,000 units at $4.29), increasing direct ownership by 0.93% to 1,086,467 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    3/16/26 4:54:18 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Hill Scott A bought $169,246 worth of shares (50,000 units at $3.38) (SEC Form 4)

    4 - CS Disco, Inc. (0001625641) (Issuer)

    3/4/26 4:18:00 PM ET
    $LAW
    Computer Software: Prepackaged Software
    Technology

    Director Goodman Robert P bought $3,275,173 worth of shares (1,026,700 units at $3.19) (SEC Form 4)

    4 - CS Disco, Inc. (0001625641) (Issuer)

    3/3/26 7:33:37 PM ET
    $LAW
    Computer Software: Prepackaged Software
    Technology

    $AMBI
    $AVTX
    $AXLA
    $BIMI
    Leadership Updates

    Live Leadership Updates

    View All

    Vongvanith Named Kinetic's First Chief Customer Officer; Brings Customer Voice to Senior Leadership

    LITTLE ROCK, Ark., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kinetic, a leader in residential and business fiber internet, has elevated the customer voice with the creation of its new chief customer officer role. The position, which is the first of its kind at Kinetic, underscores the company's customer-obsessed approach and commitment to delivering better technology, service, value and experience for customers. Industry leader Stacie Vongvanith will be Kinetic's first CCO. Drawing on her years of telecom, cable and fiber internet experience, Vongvanith will enhance Kinetic's customer experience, identify pain points and act quickly to solve them, helping the company continue to raise the bar for

    2/17/26 8:00:00 AM ET
    $UNIT
    Real Estate Investment Trusts
    Real Estate

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sezzle Announces Chief Financial Officer Transition

    Minneapolis, MN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ:SEZL) (Sezzle or Company) // Sezzle, a purpose-driven digital payment platform, today announced the appointment of Lee Brading as Chief Financial Officer ("CFO"), effective February 1, 2026. Brading will succeed Karen Hartje, who served as CFO and principal financial officer under a Consulting Agreement since November 1, 2025, following her announcement of retirement after nearly eight years as CFO of Sezzle. Hartje will remain engaged as a consultant to ensure an orderly transition.  "Karen has been instrumental in Sezzle's evolution from a private startup to a publicly traded, profitable fintech company," said Char

    1/29/26 4:14:17 PM ET
    $SEZL
    Finance: Consumer Services
    Finance

    $AMBI
    $AVTX
    $AXLA
    $BIMI
    Financials

    Live finance-specific insights

    View All

    ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

    ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread and perpetuation of inflammation by uniquely inhibiting ASC specks. Lead indication: Cardiometabolic conditions associated with obesityValue driving milestones: File IND Q4-2026; Phase 1 SAD read-out Q1-2027 Cholesterol Efflux Mediator VAR 200 is expected to be a disease-modifying renal drug by targeting unaddress

    3/31/26 5:05:00 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically

    3/19/26 12:00:00 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as

    3/19/26 10:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMBI
    $AVTX
    $AXLA
    $BIMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Trinseo PLC

    SC 13G - Trinseo PLC (0001519061) (Subject)

    12/17/24 5:11:10 PM ET
    $TSE
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13D/A filed by IBEX Limited

    SC 13D/A - IBEX Ltd (0001720420) (Subject)

    12/6/24 7:28:26 PM ET
    $IBEX
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by IBEX Limited

    SC 13D/A - IBEX Ltd (0001720420) (Subject)

    11/22/24 4:17:06 PM ET
    $IBEX
    EDP Services
    Technology